Olmesartan Medoxomilo + Hidroclorotiazida Ratiopharm (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil + Hydrochlorothiazide Ratiopharm, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension, often in combination with a thiazide diuretic, to lower blood pressure in adult patients.

GNH USA supplies Olmesartan Medoxomil + Hydrochlorothiazide Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable logistics for global distribution.

Olmesartan/HCTZ is used to manage hypertension by targeting the renin‑angiotensin system and promoting diuresis.

Essential hypertension: reduces elevated systolic and diastolic blood pressure. Controlled hypertension: helps maintain target blood pressure levels. Hypertension with fluid retention: combines vasodilation and diuretic action to improve blood pressure control.

The combination may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: light‑headed feeling, especially after standing. - Headache: mild to moderate pain. - Increased urination: more frequent bathroom visits. - Electrolyte imbalance (low potassium): mild muscle cramps. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden loss of renal function. - Hyperkalaemia: dangerously high potassium levels. - Allergic reaction: rash, swelling, or difficulty breathing. - Pancreatitis: severe abdominal pain.

Before prescribing, clinicians should consider several safety measures. - Monitor blood pressure: ensure adequate control and avoid excessive lowering. - Assess renal function: check serum creatinine and eGFR regularly. - Check electrolytes: especially potassium and sodium levels. - Avoid use in severe hepatic impairment: limited metabolism may increase exposure. - Use caution during pregnancy: potential fetal risk, evaluate benefit‑risk. - Store at room temperature: keep in original container, protect from moisture.

Olmesartan/HCTZ can affect or be affected by other medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): risk of hyperkalaemia. - ACE inhibitors or other ARBs: additive renal impairment. - NSAIDs (e.g., ibuprofen): may blunt antihypertensive effect. - Lithium: increased lithium toxicity.

Moderate Interactions (Monitor Closely): - Other thiazide diuretics: additive hypotension. - Beta‑blockers: enhanced blood‑pressure lowering. - CYP450 inhibitors (e.g., ketoconazole): may raise olmesartan levels. - Antacids containing aluminium or magnesium: reduce absorption. - Warfarin: monitor INR for possible changes.